DC Chemicals · Product datasheet

Cangrelor sodium — Datasheet

CAT. NO. DC22425

Product page and current package options

ParameterValue
Chemical Name(dichloro((((((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-((2-(methylthio)ethyl)amino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)methyl)phosphonic acid, tetrasodium salt
CAS No.163706-36-3
SynonymsAR-C69931MX; AR C69931MX; ARC69931MX; AR-C69931; AR C69931; ARC69931; Cangrelor; Cangrelor tetrasodium salt
FormulaC17H21Cl2F3N5Na4O12P3S2
M.Wt864.29
SMILESO=P(C(Cl)(P(O[Na])(O[Na])=O)Cl)(OP(OC[C@H]1O[C@@H](N2C=NC3=C(NCCSC)N=C(SCCC(F)(F)F)N=C23)[C@H](O)[C@@H]1O)(O[Na])=O)O[Na]
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist[1][2].

In Vitro

Cangrelor tetrasodium is the only potent intravenous direct and specific adenosine diphosphate (ADP) P2Y12 receptor antagonist[1]. Cangrelor tetrasodium has pKb of 8.6-9.2 for hP2Y12 receptor[3].

In Vivo

Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice[2].

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation